Further, dual-targeted TIGIT.SynNotch.aCD73 iNK cells demonstrated enhanced anti-tumor responses over either WT or engineered iNK cells lacking the aCD73 domain, demonstrating the value of simultaneous targeting of CD73 and TIGIT in an adoptive transfer setting and the need for the transcriptional activation and translation of CD73-blocking scFv following TIGIT-CD155 engagement (Supplementary Fig. 17B, C). Here, PVR is linked to neoplasm.